Piper Sandler Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $130.00. The company’s shares closed last Friday at $42.37.

According to TipRanks, Raymond is a 4-star analyst with an average return of 3.6% and a 48.80% success rate. Raymond covers the Healthcare sector, focusing on stocks such as Biogen, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $91.38 average price target, representing an 115.67% upside. In a report released today, RBC Capital also initiated coverage with a Buy rating on the stock with a $77.00 price target.

Based on Ultragenyx Pharmaceutical’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $127.39 million and a GAAP net loss of $123.19 million. In comparison, last year the company earned a revenue of $103.35 million and had a GAAP net loss of $151.83 million

Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RARE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical (RARE) Company Description:

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.